Co-Diagnostics, Inc. (CODX): Amendment to Equity Distribution Agreement with Maxim Group LLC
Key Points from the SEC Form 8-K Filing (Dated July 27, 2026)
- Material Definitive Agreement: Co-Diagnostics, Inc. (“the Company”) has announced a First Amendment to its Equity Distribution Agreement with Maxim Group LLC (“Agent”), originally dated October 20, 2025.
- Removal of Share Limit: The amendment removes the previous cap on the number of shares that can be sold under the agreement. Previously, the Agent could sell common stock up to an aggregate offering price of \$10 million. Now, there is no such limit, subject only to the number of shares registered and authorized by the Company.
- New Registration Statement: The Company has filed a new base registration statement on Form S-3 (File No. 333-295803), declared effective May 15, 2026, and will use a prospectus supplement dated July 27, 2026 to register additional shares for sale under the agreement.
- Offering Details: The Company may issue and sell, through Maxim Group, shares of common stock, par value \$0.001 per share. These shares are all authorized but unissued shares.
- Legal Opinion: Dorsey & Whitney LLP has provided a legal opinion confirming that shares issued under this agreement will be validly issued, fully paid, and non-assessable, under Utah law.
- Temporary Restriction on Issuance: In connection with the amendment and the new prospectus supplement, the Company agreed with investors under a Securities Purchase Agreement dated May 19, 2026, to refrain from issuing new shares or entering agreements for issuance, or filing registration statements or prospectuses (including amendments/supplements) until 5:00 pm Eastern Time on August 14, 2026.
- Trading Details: CODX’s common stock is registered on NASDAQ under the trading symbol “CODX”.
- Emerging Growth Company Status: CODX is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Potential Shareholder Impacts & Price Sensitivity
- Unlimited Share Sales: The removal of the share cap could significantly affect the Company’s ability to raise capital via at-the-market offerings. This increases flexibility for the Company but may also raise dilution concerns for existing shareholders, especially if large volumes of stock are sold.
- Registration of Additional Shares: The new registration statement and prospectus supplement allow for up to \$7,901,383 of common stock to be offered. This is a substantial amount and signals the Company’s intention to access capital markets more aggressively.
- Temporary “Quiet Period”: Until August 14, 2026, the Company cannot issue new shares or announce plans to do so. Investors should monitor August 14 as a key date—after this, new issuances or announcements could occur, potentially affecting share price.
- Legal Assurance: The legal opinion from Dorsey & Whitney LLP removes uncertainty regarding the validity of shares issued, giving investors confidence in the legal standing of the offering.
- No Emerging Growth Company Benefits: CODX does not qualify as an emerging growth company, which means it does not benefit from certain reduced compliance and reporting obligations. This could affect costs and regulatory scrutiny.
Details of the Amendment
The First Amendment to the Equity Distribution Agreement between Co-Diagnostics and Maxim Group LLC restates the introductory paragraph and modifies Sections 2(a) and 7(a) to remove any cap on the number of shares that may be sold. Sales may now occur up to the number of shares registered and authorized in the Company’s articles of incorporation and under effective registration statements.
The amendment defines “New Registration Statement” as any new Form S-3 (or successor form) filed after October 20, 2025, including all amendments and prospectus supplements, as well as any registration statement filed under Rule 462(b) to register additional shares.
Upon effectiveness of a new registration statement, references in the agreement to “Registration Statement,” “Base Prospectus,” “Prospectus,” etc., will refer to the new registration statement and related documents.
The Company has committed to a temporary restriction on issuing new shares or announcing issuances, lasting until 5:00 pm ET on August 14, 2026, in connection with previous investor agreements.
The legal opinion (filed as Exhibit 5.1) confirms that shares issued per the amended agreement and prospectus supplement will be validly issued, fully paid, and non-assessable.
Conclusion & Investor Considerations
- The amendment increases the Company’s flexibility in capital raising but also introduces potential dilution risk for shareholders.
- The temporary quiet period ends August 14, 2026—investors should be alert for any new issuance announcements after this date.
- The legal opinion removes risk over the validity of issued shares.
- These developments are significant and could impact share price, especially depending on the volume of shares issued post-August 14.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions related to Co-Diagnostics, Inc. The information is based on SEC filings and may contain forward-looking statements subject to risks and uncertainties.
